MedPath

Comparative Evaluation of CTG With and Without rhPDGF- BB Using Modified Coronally Advanced Tunnel for Root Coverage

Not Applicable
Completed
Conditions
Gingival Recession
Registration Number
NCT03676088
Lead Sponsor
Krishnadevaraya College of Dental Sciences & Hospital
Brief Summary

The present study is a human, prospective, single centre, single blind, comparative controlled randomized clinical trial for the treatment of Miller's Class I, II or combination of class I and II mandibular recession and comparing the clinical outcomes prior to and 6 months after treatment. The trial is in accordance to the Consolidated Standards of Reporting Trials (CONSORT) criteria, 2010.

Detailed Description

24 recession defects were selected in patients who were systemically and periodontally healthy, satisfying the determined inclusion criteria. Patients with at least two or more teeth having Miller's class I , II or combination of class I and II mandibular recession defects were included in the study. A detailed, thorough medical and dental history was obtained and each patient was subjected to comprehensive clinical and radiological examination. All patients were informed about the nature of the study, surgical procedure involved, potential benefits and risks associated with the surgical procedure and a written informed consent was obtained from all patients.

The patients were assigned into two treatment groups (test and control). The test group was treated with recombinant human Platelet Derived Growth Factor-BB and Modified Coronally Advanced Tunnel +Connective Tissue Graft whereas the control group was treated by Modified Coronally Advanced Tunnel +Connective Tissue Graft alone.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
6
Inclusion Criteria
  • Patients fulfilling the following criteria were included in the study:-

    • Two or more teeth with Miller's class I and II or combined class I and II recession defects in mandibular anteriors.
    • Age group 21-58 years.
    • Patients with healthy or treated periodontal conditions.
    • Patients willing to participate in the study.
    • Absence of uncontrolled medical conditions.
    • Patients with full mouth plaque score </= 10%(O'Leary 1972)
    • Patients with esthetic concerns.
    • Patients with thick gingival biotype >0.8mm
Exclusion Criteria
  • Pregnant or lactating females.
  • Tobacco smoking.
  • Uncontrolled medical conditions.
  • Untreated periodontal conditions.
  • Use of systemic antibiotics in the past 3 months.
  • Patients treated with any medication known to cause gingival hyperplasia.
  • Drug and alcohol abuse
  • No occlusal interferences.
  • Patient with a known hypersensitivity to rhPDGF-BB.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Gingival recession depth (GRD)6 months

measured as the distance from the Cemento Enamel Junction to the gingival margin

2. Gingival Recession Width (GRW)6 months

measured as the distance between the mesial gingival margin and distal gingival margin

Mean root coverage(MRC)6 months

(Baseline recession depth - 6 month recession depth/Baseline recession depth)\*100

Complete root coverage(CRC)6 months

root coverage regarded as complete with gingival margin located at the level of Cemento Enamel Junction

coverage esthetic score(RCES)6 months

The Aesthetic evaluation was performed according to the root coverage aesthetic score system (RES)

Five Variables evaluated which are as follows:

1. Level of Gingival margin (GM)

2. Marginal Tissue Contour (MTC)

3. Soft Tissue Texture (STT)

4. Mucogingival Junction(MJ) alignment

5. Gingival Colour (GC)

Secondary Outcome Measures
NameTimeMethod
probing pocket depth (PD)6 months

measured as the distance from the gingival margin to the base of gingival sulcus

clinical attachment level (CAL)6 months

measured as Gingival Recession Depth + Probing Depth

width of keratinized tissue (KTW)6 months

measured as the distance from the mucogingival junction to the gingival margin , with the mucogingival junction location determined using a visual method (Schiller's Potassium Iodide Solution).

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.